Report
Pharma Mar : Q3 preview: oncology sales to normalize after the Q2 ‘early-access’ adjustment
>Oncology revenues normalise and return to the levels seen in Q1 2023/Q4 2022 - Q3 2023 results will be released next 26 October. We expect total revenue to decrease by 27% y-o-y to € 30m explained by lower royalties (-50% y-o-y to € 7m), lower licences (-19% to € 6m) and the normalisation of the oncology revenues (-21% to € 17m vs the € 28m seen in Q2 that were inflated by the one-off ‘early-access’ adjustment in Lurbinectedin. At the EBITDA level, we expect a slight...
Underlying
Pharma Mar SA
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.